spacer
home > white papers > Maximize the ROI of Your Post-Approval Research - Bioclinica
WHITE PAPERS

Bioclinica

phone +1 609-936-2896
email info@bioclinica.com
web http://www.bioclinica.com/

Maximize the ROI of Your Post-Approval Research

Expenditures in post-approval (Phase IV) research are going up across the pharmaceutical, biotech and medical device industries. Given the resources you’ve committed to post-approval research, you may be wondering if you’re getting the greatest possible return on your investment.

Discover how to harness the power of post-approval research to increase data collection, reduce resource burn, save money, and maximize your ROI!
Maximize the ROI of Your Post-Approval Research
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Everything Genetic launches Next Generation Sequencing service as part of its public-private partnership with Berkshire and Surrey Pathology Services

NANTWICH, CHESHIRE and GUILDFORD, SURREY, NOVEMBER 2022. Everything Genetic, a fast-growing UK business offering genetic testing services for the diagnosis, prevention and treatment of a range of cancers, has partnered with Berkshire and Surrey Pathology Services (BSPS), an NHS Pathology Network, to provide Next Generation Sequencing (NGS) services to healthcare professionals and customers across the UK.
More info >>


White Papers

Accelerating the Time from DNA to Material

Merck

Cell line development is a critical step in upstream process development for monoclonal antibodies (mAbs). Unfortunately, the search for the bestproducing clone can be labor- and resource-intensive and is often compared with looking for a needle in a haystack. Cells must first be engineered to produce the biologic of interest and the cell line generated from a high producing clone must deliver a sufficiently high titer to support clinical studies, and ultimately commercialization of the therapeutic.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement